Dublin, Oct. 21, 2013 (GLOBE NEWSWIRE) -- Research and Markets
( http://www.researchandmarkets.com/research/hh...untingtons ) has announced the addition of the "Huntingtons Disease Therapeutics - Global Strategic Business Report" report to their offering.
This report analyzes the worldwide markets for Huntingtons Disease Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2018. Also, a six-year historic analysis is provided for these markets.
Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.
Key Topics Covered
I. Introduction, Methodology & Product Definitions
- Study Reliability and Reporting Limitations
- Disclaimers
- Data Interpretation & Reporting Level
- Quantitative Techniques & Analytics
- Product Definitions and Scope of Study
II. Executive Summary
1. INDUSTRY OVERVIEW
- Prelude
- Huntington's Disease - Few Quick Facts
- Market Opportunity
- Competition in the Global HD Therapeutics Market is Nonexistent
- Effectiveness of Current HD Management Strategies
- HD Treatment and Drugs
- Alternative Treatment Approaches for Huntington's disease
- Alternate Approaches and Therapies
- Off-Label Prescriptions
- Select Off-Label Drugs Prescribed for Huntington's Disease
2. HD THERAPEUTICS MARKET TRENDS
- Companies Boost R&D Spending for HD Therapeutics
- Improved Diagnostics Fueling Interest of Companies in HD Research
- Support Organizations Play an Instrumental Role in HD Research and Awareness
- Public-Private Partnerships: A Shot in the Arm
- HD Research Attracts Big Pharma Investment
- Pre-Symptomatic Patients to Expand Market Base
- HDSA Pushes for Improvement in Medicare Funding for Huntington's Disease
- GINA for Reducing Discrimination Faced by People with HD
3. HD RESEARCH AND DRUG PIPELINE
- A Quick Primer
- Drug Development Pipeline Reveals Promising Picture
- Select Drugs and Supplements in HD Research Pipeline (2011)
- Overview of Select Pipeline Drugs
- Huntexil™ (Pridopidine)
- RP103 (DR Cysteamine)
- PBT2
- Other Novel Approaches for HD Treatment
- Cellular Delivery of Neurotropic Agents
- Cogane
- COPREXA
- Histone Deacetylases (HDAC)
- Melatonin, Coenzyme Q-Free Radical Scavengers
- RNAi - RNA Interference
- Small Molecule Inhibitor of Polyglutamine Interaction
- TELOMICS™
4. RESEARCH BREAKTHROUGHS IN HD ARENA
- Lund University Researchers Successfully Map Functionality of Hypothalamus in HD
- MIB, University of Lisbon and University of Leicester Demonstrate Latest Findings on KMO Enzyme
- Latest TRACK-HD Findings Demonstrate Early Identification of Huntingtons Disease Progression in Patients
- Researchers at BUSM, MGH, Columbia University and McLean BTRC Demonstrate Impact of Huntingtons Disease on Human Brain
- Researchers Demonstrate Significance of TFEB and PGC-1alpha Proteins in Prevention of HD
- Florey Neuroscience Institutes Demonstrates Importance of Cognitive Stimulation in HD Patients
- University of Wisconsin-Madison Waisman Center Demonstrates Stem Cell Therapy Potential for Treating HD
- NUI Galway Announces Discovery of Experimental Drugs with Potential for Slowing Progress of HD
- Lawrence Berkeley National Laboratory Designs Compound for Suppressing HD Symptoms
- Development of HD Affected Human Brain Cells for Investigative Purposes
- Device Implant in Brain Exhibits Therapeutic Potential for HD
- Sangamo Biosciences on Path to Discover a Therapy for HD
- Scientists at University of Rochester Medical Center Demonstrate Use of Coenzyme Q10 for Reduction of Oxidative Damage in HD Patients
- McMaster University Discovers New Drug Candidate for Huntingtons Disease
- University of Central Florida Researchers Test Role of DRP1 Protein in HD
- CMMT and Brain Research Centre Decode Cellular Mechanism Related to Alteration of Brain Cell Function in HD
5. AN OVERVIEW OF HUNTINGTON'S DISEASE
- Introduction
- Historical Background
- Prognosis
- Stages of HD
- Symptoms and Signs
- Physical Symptoms
- Emotional Symptoms
- Mental Symptoms
- Genetics of Huntingtons Disease
- Inheritance
- Mechanism
- Functions of HTT
- Effects of mHTT on Cells
- Macroscopic Effects of mHTT
- Diagnosis of HD
- Clinical Diagnosis
- Embryonic Diagnosis
- Differential Diagnosis
- Diagnostic Tests for Huntingtons Disease
- Confirmatory Diagnostic Test
- Pre-symptomatic Diagnostic Test
- Prenatal Diagnostic Test
- Treatment Options
- Nutrition and Eating
- Social Activity
- Speech Therapy
- Physical Therapy
- Occupational Therapy
- Medication
6. CLINICAL TRIALS
- Dimebon Fails Horizon Trials for Treatment of Cognitive Dysfunction in HD Patients
- Huntexil's Trials Prove only Borderline Benefits
- AFQ056 in Phase II Clinical Study for Treatment of Chorea
- Siena Biotech S.p.A. Undertakes Preparatory Steps for Phase II study of SEN0014196
- Elontril in the Set-up Stage for Phase II Study
- Alnylam Presents Positive Pre-clinical Data for its siRNA for silencing the Mutant HTT
7. RECENT INDUSTRY ACTIVITY
- Roche Enters into Alliance with Isis Pharmaceuticals
- Isis and CHDI Collaborate with KineMed
- Omeros Receives IND Approval for OMS824 for Huntington's Disease
- Teva Pharmaceutical Industries Signs Asset Transfer Agreement with NeuroSearch
- uniQure and Benitec Biopharma Ink Cross- Licensing Agreement
- Evotec and CHDI Foundation Extend Collaboration
- Raptor Acquires Exclusive Rights to Cysteamine and Associated Compounds
- GNS Healthcare Enters into Collaboration with CHDI Foundation
- Lundbeck Collaborates with CHDI Foundation for HD Research
- Horizon Discovery Collaborates with Institute of Neurology, London
- Thomson Reuters and CHDI Foundation Enter into MetaMiner Partnership
- Targeted Genetics Changes Name to AmpliPhi Biosciences
- Intellect Neurosciences Commences Initial Development of CONJUMAB-A Platform Technology
- CHDI Foundation and Galenea Collaborate
- CHDI Foundation and Isis Pharmaceuticals Renew Collaboration
- Sage Bionetworks and Takeda Pharmaceutical Enter into Research Alliance
- Sage Bionetworks Extends Partnership with CHDI Foundation
- University of Dundee and GlaxoSmithKline to Collaborate over HD Research
8. CORPORATE ACTIVITY IN THE RECENT PAST - A PERSPECTIVE BUILDER
- Gladstone Institute and Taube-Koret to Collaborate with Institute for Systems Biology
- Alliance Pharma Concludes Distribution Deal with Biovail
- Lundbeck Acquires LifeHealth
- Lundbeck Acquires Ovation
- Biovail Purchases Global Rights for Tetrabenazine from Cambridge
- Raptor Pharmaceuticals, TorreyPines Conclude Merger
- Cambridge Laboratories Enters into New Agreements for Marketing Xenazine® in North America
- CHDI Foundation Inks Agreement with AMRI for Drug Discovery
- Phytopharm Inks Agreement with CHDI Foundation to Evaluate Cogane
- NeuroSearch Repurchases Global Rights to ACR16
- Raptor Pharmaceuticals Enters into Collaboration with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial
- Targeted Genetics Acquires Full Rights from Sirna Therapeutics to siRNA Development Program
- Cambridge Laboratories Receives Marketing Approval for Tetrabenazine from Agencia Espanola de Medicamentos y Productos Sanitarios
- Cambridge Laboratories Inks and Renews Agreements with Taiwan, New Zealand, Finland and Australia
- CHDI Inked Collaboration Agreements with Galapagos
- Biovail Acquires Prestwick Pharmaceuticals
- Ovation Pharmaceuticals Acquires License to Commercialize Xenazine® in the US
- Aegera Therapeutics Inks License Agreement with Neurologix
9. FOCUS ON SELECT PLAYERS
- Alnylam Pharmaceuticals, Inc. (US)
- AmpliPhi Biosciences Corp (US)
- Ceregene, Inc. (US)
- Cortex Pharmaceuticals, Inc. (US)
- Intellect Neurosciences Incorporation (US)
- Prana Biotechnology Limited (Australia)
- Raptor Pharmaceuticals Corp. (US)
- Teva Pharmaceutical Industries Ltd (Israel)
- Trophos SA (France)
- Valeant Pharmaceuticals International, Inc. (Canada)
- Vertex Pharmaceuticals Incorporated (US)
10. GLOBAL MARKET PERSPECTIVE
III. Market
1. The United States
2. Europe
3. Rest Of World
IV. Competitive Landscape
Companies Mentioned
The report profiles 35 companies including
- Alnylam Pharmaceuticals
- AmpliPhi Biosciences Corp.
- Ceregene
- Cortex Pharmaceuticals
- Intellect Neurosciences Incorporation
- Prana Biotechnology Limited
- Raptor Pharmaceuticals Corp.
- Teva Pharmaceutical Industries Ltd.
- Trophos SA
- Valeant Pharmaceuticals International
- Vertex Pharmaceuticals Incorporated.
For more information, including full list of companies profiled, please visit http://www.researchandmarkets.com/research/hh...untingtons
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System
